에스트로겐 수용체 양성 유방암 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료법별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

The global estrogen receptor positive breast cancer treatment market size was estimated at USD 23.1 billion in 2025 and is projected to grow from USD 24.9 billion in 2026 to USD 42.4 billion by 2033, growing at a CAGR of 7.9% from 2026 to 2033. North America dominated with a revenue share of 39.0% in 2025. Several key factors drive market growth, including advancements in drug development, increasing cancer awareness and screening, rising incidence rates, and strategic collaborations.

These drivers are significantly shaping the landscape of ER+ breast cancer treatments, facilitating the introduction of innovative therapies, improving patient outcomes, and expanding access to cutting-edge treatments. According to the World Health Organization (WHO), Breast cancer, with over 2.3 million cases annually, is the most common cancer in adults and a leading cause of female cancer-related deaths, particularly in low- and middle-income countries. This growing global disease burden continues to increase the demand for effective treatment options, including targeted therapies for estrogen receptor positive (ER+) breast cancer. According to the data from the American Cancer Society, breast cancer is the most common cancer among women, with an estimated 310,720 new cases expected in the US alone in 2024. The increasing number of diagnoses is driving demand for advanced treatment options and encouraging pharmaceutical companies to invest in the development of more effective and personalized ER+ breast cancer therapies.

Recent innovations in drug development are a significant driver for the market growth. New therapies, including novel aromatase inhibitors, selective estrogen receptor degraders (SERDs), and targeted therapies, are being introduced. For instance, in January 2023, the FDA approved Orserdu, a new oral medication intended for the treatment of metastatic estrogen receptor positive, HER2-negative breast cancer with an ESR1 mutation. These advancements reflect the sector's focus on developing more effective, personalized treatment strategies.

Increased awareness regarding breast cancer symptoms and the importance of early detection has led to more women participating in regular screening programs. For instance, Susan G. Komen and the American Cancer Society have launched campaigns to educate women about self-examinations and mammography screenings. As awareness grows, so does the demand for effective treatments tailored specifically for those diagnosed with ER+ subtypes.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Estrogen Receptor Positive Breast Cancer Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High incidence and prevalence of ER+ breast cancer
    • 3.2.1.2. Availability of endocrine therapies targeting ER
    • 3.2.1.3. Increasing adoption of targeted therapies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited treatment options for resistant cases
    • 3.2.2.2. High costs associated with advanced therapies
• 3.3. Estrogen Receptor Positive Breast Cancer Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Global Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Dashboard
• 4.2. Global Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Movement Analysis
• 4.3. Global Estrogen Receptor Positive Breast Cancer Treatment Market by Treatment, Revenue
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Targeted therapy market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Hormonal Therapy
  • 4.6.1. Hormonal therapy market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Radiation Therapy
  • 4.7.1. Radiation therapy market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Other
  • 4.8.1. Other market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Estimates & Trend Analysis

• 5.1. Global Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Dashboard
• 5.2. Global Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Movement Analysis
• 5.3. Global Estrogen Receptor Positive Breast Cancer Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Specialty clinics market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Estrogen Receptor Positive Breast Cancer Treatment Market: Regional Estimates & Trend Analysis by Treatment, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key company market share analysis, 2023
  • 7.2.3. Radius Health, Inc.
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Sanofi
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. F. Hoffmann-La Roche Ltd
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. AstraZeneca
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Lilly
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. EQRx, Inc.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Gilead Sciences, Inc.
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Sermonix Pharmaceuticals
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Tyme Limited
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. Genentech, Inc.
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives